Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDKN1A | P38936 | 1/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243650 | 0.90 | CDKN1A (0.53) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| SCHEMBL3241433 | 0.88 | CDKN1A (0.54) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| SCHEMBL1874348 | 0.85 | CDKN1A (0.59) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| SCHEMBL5812540 | 0.82 | CDKN1A (0.59) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| SCHEMBL1877621 | 0.81 | CDKN1A (0.54) | CDKN1ATLR8BRAFKDM4EMAP2K1 | |
| SCHEMBL2107990 | 0.80 | CDKN1A (0.55) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| SCHEMBL1877962 | 0.80 | CDKN1A (0.55) | CDKN1ATLR8BRAFKDM4EMAP2K1 | |
| SCHEMBL5809040 | 0.80 | CDKN1A (0.56) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| Lorediplon SCHEMBL29376531 | 0.79 | CDKN1A (0.54) | CDKN1ATLR8BRAFKDM4EALDH1A1 | |
| Lorediplon SCHEMBL1316601 | 0.79 | CDKN1A (0.54) | CDKN1ATLR8BRAFKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | claimed |
| EP-1899343-B1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INT (ES) | 2010-05-12 | — | — | EP | claimed |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | US | claimed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | claimed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | claimed |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | FERRER INTERNACIONAL, S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACTIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | disclosed |
| EP-1899343-B1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INT (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | US | disclosed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | disclosed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | CDKN1A 1754/4885TLR8 4193/4885BRAF 439/4885 |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | GABRA5, GABRA1, GABBR1 | CDKN1A 1723/4885TLR8 4221/4885BRAF 859/4885 |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | CDKN1A 1754/4885TLR8 4193/4885BRAF 439/4885 |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | GABRA5, GABRA1, RYR1 | CDKN1A 1754/4885TLR8 4193/4885BRAF 439/4885 |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | CDKN1A 1754/4885TLR8 4193/4885BRAF 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.